Roche's Elecsys GALAD scores Receive the US FDA's Breakthrough Device Designation for Earlier Diagnosis of Hepatocellular Carcinoma
Shots:
- The GALAD score combines gender and age with the biomarker results of the Elecsys AFP- AFP-L3 and PIVKA-II and is intended to aid diagnosis of early-stage HCC
- The Elecsys GALAD will be the first GALAD score with regulatory approval to be used as IVD targeting the improvement in diagnostic workflows in the management of chronic liver disease
- The Elecsys GALAD score in combination with blood-based biomarkers support clinicians by providing them accurate and timely information to make earlier interventions- thus improves patient’s outcomes and reduces the mortality rate in patients with HCC
Click here to read full press release/ article
Ref: Roche | Image: Roche
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com